JPWO2023118507A5 - - Google Patents

Info

Publication number
JPWO2023118507A5
JPWO2023118507A5 JP2024538291A JP2024538291A JPWO2023118507A5 JP WO2023118507 A5 JPWO2023118507 A5 JP WO2023118507A5 JP 2024538291 A JP2024538291 A JP 2024538291A JP 2024538291 A JP2024538291 A JP 2024538291A JP WO2023118507 A5 JPWO2023118507 A5 JP WO2023118507A5
Authority
JP
Japan
Prior art keywords
alkylene
alkyl
heterocycloalkyl
cycloalkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503502A (ja
JP2025503502A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/087613 external-priority patent/WO2023118507A2/en
Publication of JP2025503502A publication Critical patent/JP2025503502A/ja
Publication of JP2025503502A5 publication Critical patent/JP2025503502A5/ja
Publication of JPWO2023118507A5 publication Critical patent/JPWO2023118507A5/ja
Pending legal-status Critical Current

Links

JP2024538291A 2021-12-22 2022-12-22 化合物及びhdac6阻害剤としてのその使用 Pending JP2025503502A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21217182.1 2021-12-22
EP21217181.3 2021-12-22
EP21217181 2021-12-22
EP21217182 2021-12-22
PCT/EP2022/087613 WO2023118507A2 (en) 2021-12-22 2022-12-22 Compounds and use thereof as hdac6 inhibitors

Publications (3)

Publication Number Publication Date
JP2025503502A JP2025503502A (ja) 2025-02-04
JP2025503502A5 JP2025503502A5 (https=) 2026-01-07
JPWO2023118507A5 true JPWO2023118507A5 (https=) 2026-01-07

Family

ID=84981649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538291A Pending JP2025503502A (ja) 2021-12-22 2022-12-22 化合物及びhdac6阻害剤としてのその使用

Country Status (9)

Country Link
US (2) US20250051319A1 (https=)
EP (1) EP4452265A2 (https=)
JP (1) JP2025503502A (https=)
KR (1) KR20240124952A (https=)
AU (1) AU2022420827A1 (https=)
CA (1) CA3239992A1 (https=)
IL (1) IL313636A (https=)
MX (1) MX2024007904A (https=)
WO (1) WO2023118507A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
MX2024007904A (es) * 2021-12-22 2024-09-18 Augustine Therapeutics Compuestos y uso de estos como inhibidores de hdac6.
IL316201A (en) 2022-04-08 2024-12-01 Eikonizo Therapeutics Inc Oxadiazole HDAC6 inhibitors and their uses
WO2024261327A1 (en) * 2023-06-21 2024-12-26 Augustine Therapeutics 2-(heteroaryl-thio)-1-(heteroaryl)ethanone compounds and use thereof as hdac6 inhibitors
KR20260025099A (ko) * 2023-06-21 2026-02-23 어거스틴 테라퓨틱스 헤테로아릴-아민 화합물 및 이의 hdac6 억제제로서의 용도
WO2024261328A1 (en) * 2023-06-21 2024-12-26 Augustine Therapeutics Amide-amine compounds and use thereof as hdac6 inhibitors
WO2026027696A1 (en) * 2024-07-31 2026-02-05 Augustine Therapeutics Thiomethyl carbonyl compounds and use thereof as hdac6 inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2005014588A1 (en) 2003-08-01 2005-02-17 Argenta Discovery Limited Substituted thienyl-hydroxamic acids having histone deacetylase activity
US20090023798A1 (en) 2007-06-15 2009-01-22 Pharmacyclics, Inc. Thiohydroxamates as inhibitors of histone deacetylase
JP5640005B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ, インコーポレイテッド Hdacおよび/またはcdk阻害剤としてのイミダゾシルピリジン化合物
GB0813403D0 (en) 2008-07-22 2008-08-27 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
US8546588B2 (en) 2010-02-26 2013-10-01 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
CA2800717A1 (en) * 2010-05-27 2011-12-01 Bayer Intellectual Property Gmbh Heterocyclic thiosubstituted alkanol derivatives as fungicides
US20130227717A1 (en) 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
JP6338601B2 (ja) 2013-03-01 2018-06-06 フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ ホスホジエステラーゼとヒストンデアセチラーゼの二重阻害剤としての新規な化合物
WO2017053360A1 (en) 2015-09-22 2017-03-30 The Board Of Trustees Of The University Of Illinois Bicyclic and tricyclic cap bearing mercaptoacetamide derivatives as histone deacetylase inhibitors
US11584733B2 (en) * 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US12310967B2 (en) 2017-12-21 2025-05-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
ES2749743B2 (es) 2018-09-21 2020-12-14 Consejo Superior Investigacion Derivados de purina inhibidores de cdc7 y su uso para el tratamiento de patologias neurologicas
WO2021133957A1 (en) * 2019-12-27 2021-07-01 Onkure, Inc. Benzimidazole compounds as hdac6 inhibitors
EP4111863A1 (en) 2021-07-02 2023-01-04 EuroChem Antwerpen Phosphorus use efficiency enhancers as plant growth promotors
MX2024007904A (es) * 2021-12-22 2024-09-18 Augustine Therapeutics Compuestos y uso de estos como inhibidores de hdac6.
US20240139187A1 (en) 2022-10-12 2024-05-02 The Children's Medical Center Corporation Selective hypothalamus permeable hdac6 inhibitors for treatment of leptin-resistant obesity

Similar Documents

Publication Publication Date Title
AU2020350745B2 (en) Fused pyridone compound, and preparation method therefor and use thereof
JP6959332B2 (ja) Usp30の阻害剤としての活性を有するシアノピロリジン誘導体
AU2010242496B2 (en) Processes for the preparation of Rivaroxaban and intermediates thereof
JP6145179B2 (ja) ヤヌス関連キナーゼ(JAK)の阻害剤としてのピロロ[2,3−d]ピリミジン誘導体
AU2014222641B2 (en) Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B
JP2024086819A (ja) 化合物、組成物、及び、方法
JP6683712B2 (ja) ネクローシス阻害薬
JP2024166311A (ja) 化合物、組成物、及び、方法
JP2020189882A (ja) Mekインヒビターおよびその使用方法
AU2015267909B2 (en) Novel compounds
NZ603427A (en) 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
ES2359071T3 (es) Derivados de 6-(piridinil)-4-pirimidona como inhibidores de la proteina tau cinasa 1.
JPWO2023118507A5 (https=)
JP2011526594A5 (https=)
JP2014500322A5 (https=)
US8399451B2 (en) Heterocyclic compounds
EP1646629A2 (en) Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
IL171894A (en) Aztidine compounds, preparations and pharmaceutical preparations containing them
WO2003027083A1 (en) Bicyclo[3,1,0]hexane containing oxazolidinone antibiotic and derivatives thereof
FR2738245A1 (fr) Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
EP4320103A1 (en) Pyrimidine based ras modulators and uses thereof
JP2013525369A (ja) スフィンゴシン−1−リン酸受容体1アゴニストとしての4−(5−イソオキサゾリルまたは5−ピラゾリル−1,2,4−オキサジアゾール−3−イル)−マンデル酸アミド化合物
RS50539B (sr) Postupak proizvodnje derivata 1,4-difenil-azetidinona
JP5712254B2 (ja) 7員ヘテロ環を有するオキサゾリジノン誘導体
JPWO2020033520A5 (https=)